|
Myocardial Infarction
|
0.510 |
AlteredExpression
|
disease |
BEFREE |
Using NOD-SCID murine model of MI and human skeletal myoblast transplantation we were able to show that SkMC administration significantly affected gene expression profile (p<0.05) (NPPB, CTGF, GATA4, SERCA2a, PLB) of the heart ventricular tissue and this change was beneficial for the heart function.
|
26457413 |
2016 |
|
Myocardial Infarction
|
0.510 |
Therapeutic
|
disease |
RGD |
Wenxin-Keli Regulates the Calcium/Calmodulin-Dependent Protein Kinase II Signal Transduction Pathway and Inhibits Cardiac Arrhythmia in Rats with Myocardial Infarction.
|
23781262 |
2013 |
|
Myocardial Infarction
|
0.510 |
Biomarker
|
disease |
CTD_human |
The messenger RNA and protein expression of SERCA were down-regulated (p < 0.01), but the expression of phospholamban messenger RNA and protein were up-regulated (p < 0.01) in MI rats compared to sham-operated rats.
|
16162791 |
2005 |
|
Myocardial Infarction
|
0.510 |
Biomarker
|
disease |
CTD_human |
The expression of SERCA mRNA and protein were downregulated (P < 0.01), but the expression of PLB mRNA and protein were upregulated (P < 0.01) in MI rats compared with sham-operated rats.
|
16026515 |
2005 |
|
Myocardial Reperfusion Injury
|
0.500 |
Therapeutic
|
phenotype |
RGD |
Luteolin inhibits apoptosis and improves cardiomyocyte contractile function through the PI3K/Akt pathway in simulated ischemia/reperfusion.
|
21934351 |
2011 |
|
Myocardial Reperfusion Injury
|
0.500 |
Biomarker
|
phenotype |
CTD_human |
Effect of beta-adrenoceptor blockers on sarcoplasmic reticular function and gene expression in the ischemic-reperfused heart.
|
10734148 |
2000 |
|
Atrial Fibrillation
|
0.450 |
AlteredExpression
|
disease |
BEFREE |
Compared with the control group, the ibrutinib group showed (1) a higher incidence and longer duration of AF with transesophageal burst stimulation; (2) increased left atrial mass, as indicated by echocardiography; (3) significant myocardial fibrosis in the left atrium on Masson trichrome staining; (4) Ca<sup>2+</sup> handling disorders in atrial myocytes, such as reduced Ca<sup>2+</sup> transient amplitude, enhanced spontaneous Ca<sup>2+</sup> release, and reduced sarcoplasmic Ca<sup>2+</sup> capacity; (5) enhanced delayed afterdepolarization in atrial myocytes; and (6) increased CaMKII expression and phosphorylation of RyR2-Ser2814 and PLN-Thr17.
|
30959203 |
2019 |
|
Atrial Fibrillation
|
0.450 |
Biomarker
|
disease |
BEFREE |
We tested the hypothesis that reduced PPP1R3A levels contribute to AF pathogenesis by reducing PP1 binding to both RyR2 and PLN.
|
31185731 |
2019 |
|
Atrial Fibrillation
|
0.450 |
Biomarker
|
disease |
BEFREE |
Atrial rhythm instability caused by Tbx5 haploinsufficiency was rescued by a decreased dose of phospholamban, a sarco/endoplasmic reticulum Ca2+-ATPase inhibitor, consistent with a role for decreased sarcoplasmic reticulum calcium flux in Tbx5-dependent AF susceptibility.
|
31609246 |
2019 |
|
Atrial Fibrillation
|
0.450 |
Biomarker
|
disease |
CTD_human |
Biobank-driven genomic discovery yields new insight into atrial fibrillation biology.
|
30061737 |
2018 |
|
Atrial Fibrillation
|
0.450 |
AlteredExpression
|
disease |
BEFREE |
For example, phospholamban, the beta-subunit MinK (KCNE1) and MIRP2 (KCNE3), and the 2-pore potassium channel TWIK-1 were upregulated in AF-VHD compared with SR-VHD, whereas the T-type calcium-channel Cav3.1 and the transient-outward potassium channel Kv4.3 were downregulated.
|
16027256 |
2005 |
|
Atrial Fibrillation
|
0.450 |
AlteredExpression
|
disease |
BEFREE |
Down-regulation of L-type calcium channel and sarcoplasmic reticular Ca(2+)-ATPase mRNA in human atrial fibrillation without significant change in the mRNA of ryanodine receptor, calsequestrin and phospholamban: an insight into the mechanism of atrial electrical remodeling.
|
10193721 |
1999 |
|
Atrial Fibrillation
|
0.450 |
Biomarker
|
disease |
HPO |
|
|
|
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this work, we have designed and synthesized an aptamer-based near-infrared fluorescence nanoprobe for fluorescence imaging of phospholamban (PLN), which is an intracellular micropeptide that affects calcium homeostasis, and is closely associated with human heart failure in the clinic.
|
30777430 |
2019 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Pathogenic variants in human phospholamban coding gene (PLN) are known to cause hereditary dilated cardiomyopathy with heart failure in an autosomal dominant mode.
|
30638982 |
2019 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The p.Arg14del founder mutation in the gene encoding phospholamban (PLN) is associated with an increased risk of malignant ventricular arrhythmia (VA) and heart failure.
|
29635323 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
One compound increases SERCA2a calcium affinity in cardiac membranes but not in skeletal, suggesting that the compound is acting specifically on the SERCA2a-PLB complex, as needed for a drug to mitigate deficient calcium transport in heart failure.
|
30135432 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mutations and post-translational modifications of PLN may lead to dilated cardiomyopathy (DCM) and heart failure.
|
29501609 |
2018 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Phospholamban (PLN) p.Arg14del cardiomyopathy is associated with an increased risk of malignant ventricular arrhythmias and severe heart failure and a poor prognosis from late adolescence.
|
28759816 |
2018 |
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, SANs from rabbits with HF had higher protein levels of phospholamban (PLB) and lower levels of hyperpolarization-activated cyclic nucleotide-gated potassium channel 4, ryanodine receptor and phosphorylated PLB than control SANs.
|
28352365 |
2017 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Phospholamban (PLN) inhibition enhances calcium cycling and is a potential novel therapy for heart failure (HF).
|
27811197 |
2017 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
To clarify whether pVHL is involved in PLN degradation in failing hearts, we used carbonylcyanide <i>m</i>-chlorophenylhydrazone (CCCP), a mitochondrial membrane potential (MMP)-lowering reagent, to mimic the heart failure condition in PLN-expressing HEK293 cells and found that CCCP treatment resulted in PLN degradation and increased interaction between PLN and pVHL.
|
29068413 |
2017 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that PLN deletion would be a promising approach to improve both mortality and cardiac function in the heart failure.
|
27992596 |
2016 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the phospholamban (PLN) gene are associated with dilated cardiomyopathy (DCM) and severe heart failure.
|
26917049 |
2016 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Herein we focus on hereditary mutants of phospholamban that are associated with heart failure, such as Arg(9)-Cys, Arg(9)-Leu, Arg(9)-His, and Arg(14)-deletion.
|
25563649 |
2015 |